Biogenesis

What Biogenesis does

Biogenesis is a Palo Alto-based, venture-backed health-technology company that builds an AI-powered platform for clinical trial site selection and feasibility assessment. The platform targets pharmaceutical companies seeking to reduce the time and cost of clinical trial startup by connecting them with high-performing clinical research sites, leveraging predictive analytics to rank sites based on historical performance data. A core technical asset is a live database of high-performing trial sites spanning multiple regions, which the platform draws on to deliver data-driven site selection recommendations.

The company was founded in 2024 and publicly launched its platform in October 2025. Biogenesis operates with a small team (1–10 employees) and is backed by Jack Altman's Alt Capital, with prior participation from Greylock, Kleiner Perkins, Formic Ventures, and Pareto Holdings across disclosed funding rounds totaling approximately $2.75 million. Co-founders Will Blair and Martin Michalko lead the company, with Aleksander Kasprzak serving as a C-suite executive.

Biogenesis employs a product-led growth model with self-serve, platform-based distribution aimed at enterprise pharmaceutical buyers. The revenue model is described as subscription or licensing-based, providing recurring access to AI-powered site selection tools and the live trial-site database. No pricing details, named customers, or revenue figures have been publicly disclosed, and operations are currently concentrated in the United States.

Name

Biogenesis

Legal name

Biogenesis

Website

https://mybiogenesis.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Biogenesis is a Palo Alto-based health-tech company building an AI-powered platform that uses predictive analytics and a live trial-site database to help pharmaceutical companies select high-performing clinical research sites and accelerate trial startup.

Ownership category

akta.pro rank

Product category

Clinical Trial Software

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

Keywords

• Clinical trial software
• AI site selection
• Feasibility assessment
• Clinical research sites
• Drug development optimization

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Platform Access/Subscription: The platform likely operates on a subscription or licensing model providing pharmaceutical companies access to the AI-powered site selection tools and the live database of clinical trial sites

Go-to-market motion1 record

Distribution channels1 record

Core offering

Biogenesis provides an AI-powered platform that improves clinical trial site selection and feasibility assessments by connecting pharmaceutical companies with high-performing clinical research sites. The platform maintains a live database of high-performing trial sites across several regions and uses AI to deliver data-driven site selection recommendations that reduce trial startup times and costs.

Product overview

Biogenesis offers a single unified AI-powered platform focused on clinical trial site selection and feasibility. The platform provides a live database of high-performing trial sites across multiple regions, enabling pharmaceutical companies to identify optimal sites for clinical research and reduce trial startup times and costs.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-Powered Clinical Trial Site Selection Platform An AI-powered platform that improves clinical trial site selection and feasibility assessments by connecting pharmaceutical companies with high-performing clinical research sites, providing a live database of high-performing trial sites across several regions.

Quantifiable outcome

• Reduces clinical trial costs and accelerates drug development timelines

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Deep 6 AI: AI-driven clinical trial patient recruitment and site matching platform serving pharma and academic medical centers. Closest direct competitor to Biogenesis, applying AI to accelerate trial feasibility and patient cohort identification.
• H1: Healthcare data platform providing clinical trial site, investigator, and patient insights to pharma. Directly comparable to Biogenesis in connecting sponsors with high-performing research sites and patient populations via AI/data.

Emerging players

• Mendel: AI platform that structures clinical and biomedical data to support trial design, patient identification, and feasibility. Overlaps with Biogenesis on the trial feasibility and cohort matching use case with similar AI-first positioning.
• Trial Library: AI-enabled trial matching and patient recruitment platform helping sponsors find eligible patients and sites. Comparable niche focus on accelerating feasibility and enrollment that overlaps with Biogenesis' core wedge.
• Antidote (now part of Bioclinica/Clario): Digital clinical trial recruitment and matching platform connecting patients to trials via AI and structured data. Directly competes with Biogenesis on the patient population matching component of its offering.
• Castor: Cloud-based clinical trial data capture and eCRF platform with growing AI features for trial operations. Adjacent competitor serving overlapping pharma/biotech customers who increasingly bundle site selection with their eClinical stack.

Broad incumbents

• IQVIA: Largest global CRO and clinical trial technology provider with deep site relationships, real-world data assets, and AI-driven feasibility tools. Represents the legacy scale competitor Biogenesis must displace in pharma site selection workflows.
• Medidata (Dassault Systèmes): Market-leading clinical trial technology platform covering EDC, randomization, and increasingly AI-enabled trial design and site management. A broad incumbent whose suite competes for the same pharma clinical operations budget as Biogenesis.
• Veeva Systems: Enterprise cloud software for life sciences, including clinical trial management (Veeva Vault CTMS) and site operations modules. Competes for pharma clinical operations wallet share and offers overlapping feasibility/site functionality as part of a broader platform.

Others

• Definitive Healthcare: Healthcare commercial intelligence and analytics platform with rich data on hospitals, physicians, and clinical trial activity. Functions as a data/insights enabler in the same site selection and feasibility workflow Biogenesis automates.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biogenesistech
• LinkedInlinkedin.com/company/mybiogenesis

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogenesis